Join colleagues to discuss current trends in health economics and outcomes research (HEOR). Shape the future of global HEOR!

- Learn of new and novel applications in the conduct and use of HEOR.
- Engage with recognized global experts in the field.
- Network with colleagues, collaborators, and clients.
- Share your research and ideas with other ISPOR members in an open and objective environment.
- Stay current on emerging trends in health care.
- Advance your career by being an active participant (e.g., attend an ISPOR Short Course or network with renowned leaders in HEOR).

ISPOR is recognized globally as the leading scientific and educational organization for HEOR and its use in health care decisions.

Who Attends?
The ISPOR sphere of influence engages global leaders in the international HEOR community of policy makers, regulators, researchers, academicians, payers, decision makers, patients, and patient groups. This multistakeholder group is invested in using science and research to make better health care decisions.

Why Attend ISPOR Glasgow?
ISPOR Glasgow provides a forum for discussion and dissemination of HEOR information. The congress is a great opportunity to present your work, collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today’s health care, ISPOR Glasgow will address medical technology development, health technology assessment, and policy and clinical decision making while exploring the theme, *The Evolution of Value in Health Care.*
Program

ISPOR GLASGOW FEATURES NEARLY 2400 PRESENTATIONS!

To give attendees the opportunity to concentrate on their preferred areas of interest, the program format will offer scientific topics of interest (e.g., modeling, PROs, HTA, etc.) at multiple session times and in a variety of presentation formats.

- **Pre-Congress Short Courses** are training courses offered across 7 HEOR topic areas. They range in skill level from introductory to advanced, and continuing education credits are available. Separate registration is required.
- **Plenary Sessions** feature thought-provoking presentations on challenging topics related to health care policy, the application of HEOR in health care decision making, or methodology.
- **Issue Panels (IP)** introduce debate with multistakeholder perspectives on new or controversial issues in HEOR.
- **Workshops (W)** discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient preferences, and health care policy.
- **ISPOR Forums (F)** are presented by ISPOR Groups on country/regional health policy, scientific research/initiatives, good practices for outcomes research, research tools, or publications.
- **Podium Presentations (P)** sessions consist of four 15-minute outcomes research presentations on a single topic (e.g. medication compliance, budget impact, oncology outcomes studies).
- **Poster Presentations** sessions contain approximately 450 research posters per session arranged by disease, topic, or health care intervention with a scheduled author discussion hour.
- **Symposia** are sponsored presentations related to ISPOR’s mission. The sponsor organization chooses a subject of interest to delegates and arranges suitable speakers.

Networking

CONNECT WITH ISPOR MEMBERS, COLLEAGUES, COLLABORATORS, AND CLIENTS!

- Meet with clients and other attendees. Schedule meetings via the ISPOR Glasgow mobile app and web platform *(available approximately one month prior to the congress)*.
- Join your ISPOR colleagues at the Social Event on Tuesday evening. Separate registration required.
- Engage in session discussions with colleagues during the morning and afternoon coffee breaks or during lunch in the Poster and Exhibit Hall.
- Explore the Exhibit Hall and find products and services that meet your needs.
- Network with student members worldwide! Join us at the Student and Faculty Welcome Reception and Student Research Showcase!

ISPOR Groups

COLLABORATE WITH MEMBERS OF YOUR ISPOR GROUPS!

- **ISPOR Regional Groups (Chapters, Networks, and Consortia)**: Join the educational, research, and policy-related activities of these groups and meet other HEOR professionals in your region of the world.
- **ISPOR Scientific and Health Policy Working Groups (Task Forces, Special Interest Groups, and Council Working Groups)**: Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Task Force Reports, manuscripts for *Value in Health*, and online tools used by decision makers and researchers around the world.
**Plenary Sessions Featured at ISPOR Glasgow**

**FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?**

There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce. While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policymakers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patient-centered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences, Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective, and then will specifically discuss the challenges and main differences with cost-effectiveness analysis from an industrial, health economics, and patient perspective.

**Moderator:** Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

**Speakers:** Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; Luke Slawomirski, Organisation for Economic Co-operation and Development (OECD), Paris, France; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe, Uppsala, Sweden; Maarten Akkerman, Medtronic, Lausanne, Switzerland

**SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?**

Health technology assessment (HTA) processes vary across jurisdictions. Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria). In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated. The speakers will present different perspectives on evaluating the value of HTA processes and a discussant will provide an economist’s view.

**Moderator:** Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

**Speakers:** Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; Nicola Allen, PhD, Precision for Value, London, UK; Zoe Garrett, MPhil, MRes, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK

**THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC**

As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the QALY, relying instead on disease-specific metrics. The large majority of payers in the pluralistic US health care market deny explicit consideration of cost effectiveness in coverage decisions, and US law forbids its use as part of the Affordable Care Act. Instead, public and private payers in the United States increasingly push financial risk onto health care providers thereby, in a sense, decentralizing the assessment of value. Health economists from the United Kingdom, the United States, and France will provide reflective views on how valuation of medical technologies has changed across time and will discuss the methodological, societal, and political forces that shaped their evolution. The speakers will also consider what the future holds for valuation in health.

**Moderator:** Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA

**Speakers:** Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Jerome Wittwer, PhD, Bordeaux University, Bordeaux, France (invited)

---

**Congress Program Committee:**

ISPOR thanks the Congress Program Committee for its contributions in developing the scientific community’s leading HEOR program.

**Program Committee Co-Chairs**

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

**Research Review Committee Co-Chairs**

Margreet G. Franken, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands

Rok Hren, PhD, University of Ljubljana, Ljubljana, Slovenia

Andrea Manca, University of York, Heslington, York, UK

Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

**Issue Panel Review Committee Co-Chairs**

René Allard, PhD, Grünenthal GmbH, Aachen, Germany

Jan Geissler, Patvocates and European Patients’ Academy (EUPATI), Munich, Germany

Camilla Palmhoj Nielsen, PhD, DEFACTUM, Aarhus, Denmark

**Workshop Review Committee Co-Chairs**

Raquel Aguilar-Ibáñez, MSc, MSD, Hoddesdon, UK

Martin Scott, MSc, Numerus Ltd., Tubingen, Germany

Allan Wailoo, PhD, University of Sheffield, Sheffield, UK
Pre-Congress Short Course Program

The ISPOR HEOR Short Course Program, offered in conjunction with ISPOR meetings around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge and technique in seven key topic areas (“Tracks”) related to health economics and outcomes research. Short courses (many with hands-on training opportunities) range in level from introductory to advanced and are taught by leading experts in the field!

Short Courses are offered Saturday, 4 November and Sunday, 5 November in the following topic areas:

**ECONOMIC METHODS**
- Introduction to Health Economic / Pharmacoeconomic Evaluations
- Cost-Effectiveness Analysis Alongside Clinical Trials
- Statistical Methods for Pharmacoeconomics & Outcomes Research
- Transferability and Relevance of Cost-Effectiveness Data Between Countries
- Budget Impact Analysis I: A 6-Step Approach
- Budget Impact Analysis II: Applications & Design Issues

**MODELING METHODS**
- Introduction to Modeling
- Development of Conceptual Models
- Pharmacoeconomic Modeling – Applications
- Bayesian Analysis – Overview and Applications
- Using DICE Simulation for Health Economic Analysis
- Understanding Survival Modeling with Application to HTA

**OBSERVATIONAL DATA METHODS**
- Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources
- Use of Propensity Scores in Observational Studies of Treatment Effects
- Use of Instrumental Variables in Observational Studies of Treatment Effects
- Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness Studies
- Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices, and Acceptance in HTA

**OUTCOMES RESEARCH METHODS**
- Meta-Analysis & Systematic Literature Review
- Network Meta-Analysis in Relative Effectiveness Research

**PATIENT PREFERENCE METHODS**
- Conjoint Analysis – Theory & Methods
- Collecting Health-State Utility Estimates for Economic Models in Clinical Studies
- NEW! Mapping to Estimate Utility Values From Non-Preference Based Outcome Measures

**PATIENT-REPORTED OUTCOMES METHODS**
- Introduction to Patient-Reported Outcomes Assessment
- NEW! Introduction to Designing Authentic and Impactful Patient-Centered Outcomes Research

**USE OF PHARMACOECONOMIC / ECONOMIC / OUTCOMES RESEARCH INFORMATION**
- Elements of Pharmaceutical / Biotech Pricing
- Introduction to Health Technology Assessment
- NEW! US Payers – An Introduction to Their Structures, Evidence Needs, and Decision-Making Process
- Risk-Sharing / Performance-Based Arrangements for Drugs and Other Medical Products
- Introduction to the Economic Analysis of Diagnostics
- Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements
- Reimbursement Systems for Pharmaceuticals in Europe
- Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications

Select courses require use of your personal laptop.

**SHORT COURSE FEES**

<table>
<thead>
<tr>
<th></th>
<th>Through 19 September 2017</th>
<th>After 19 September 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HALF DAY COURSES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>€395 (US$430)</td>
<td>€445 (US$485)</td>
</tr>
<tr>
<td>Clinical/Government/Academia</td>
<td>€295 (US$320)</td>
<td>€345 (US$375)</td>
</tr>
<tr>
<td>Full-Time Students/Patient Representatives</td>
<td>€100 (US$110)</td>
<td>€115 (US$125)</td>
</tr>
<tr>
<td><strong>ALL DAYS COURSES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard</td>
<td>€790 (US$860)</td>
<td>€890 (US$970)</td>
</tr>
<tr>
<td>Clinical/Government/Academia</td>
<td>€590 (US$645)</td>
<td>€690 (US$750)</td>
</tr>
<tr>
<td>Full-Time Students/Patient Representatives</td>
<td>€200 (US$220)</td>
<td>€230 (US$250)</td>
</tr>
</tbody>
</table>

See [www.ispor.org/Event/ShortCourses/2017Glasgow](http://www.ispor.org/Event/ShortCourses/2017Glasgow) for Short Course schedule and descriptions, as well as to register.
Congress Program

ISPOR Glasgow features three thought-provoking plenary sessions and nearly 2400 presentations in the form of workshops, issue panels, forums, symposia, podium presentations, and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real world data, and clinical, economic, and patient-reported outcomes. **Congress registration is required!**

**SATURDAY, 4 NOVEMBER**

8:00-17:00  SHORT COURSES FULL DAY  (Separate registration required)

17:30-18:30  EDUCATIONAL SYMPOSIUM
The Evolving Approach to Drug Value Assessment in Global Markets  (Sponsored by Health Strategies Group)

18:45-19:45  EDUCATIONAL SYMPOSIUM  (Sponsored by Novartis)

**SUNDAY, 5 NOVEMBER**

8:00-17:00  SHORT COURSES  (Separate registration required)

17:30-18:30  EDUCATIONAL SYMPOSIUM
Evaluating Survival Benefits in Technology Appraisals of Innovative Oncology Drugs: Challenges and Practical Solutions  (Sponsored by Analysis Group)

18:45-19:45  EDUCATIONAL SYMPOSIUM  (Sponsored by Mundipharma International)

**MONDAY, 6 NOVEMBER**

7:30-8:30  EDUCATIONAL SYMPOSIUM
Real-World Evidence to Support Regulatory Approvals Based on Tumor Biomarkers in Oncology Research  (Sponsored by Cardinal Health)

8:30-19:30  EXHIBIT HOURS

8:45-13:45  POSTERS - SESSION I

8:45-10:45  WELCOME & FIRST PLENARY SESSION
Where Is the Value in Value-Based Health Care?

10:45-11:15  BREAK, EXHIBITS & POSTERS - SESSION I

11:15-12:15  BREAKOUT SESSION
IP1: Pragmatic Clinical Trials to Estimate Treatment Effects: Are They Worth the Effort?
IP2: How to Improve Consistency of Orphan Drug Pricing and Reimbursement in Europe? Application of the 'Orph-Val' Principles in Germany, France, and the United Kingdom
W1: Where Do We Need Good Research Practice Guidance in Health Technology Assessment?
W2: Patient Powered Registries: Useful for Health Technology Assessment or Not?
P1: Cost-Effectiveness Studies
P2: Cancer Studies

12:15-14:15  LUNCH, EXHIBITS & POSTERS - SESSION I

12:45-13:45  EDUCATIONAL SYMPOSIUM
HTA V2.0: The Relevance of Real-World Evidence in Value Frameworks and Its Relation With Regulatory and Health Technology Assessment Convergence  (Sponsored by QuintilesIMS)

12:45-13:45  POSTER AUTHOR DISCUSSION HOUR - SESSION I

14:15-15:15  BREAKOUT SESSION
IP3: Unmet (Medical) Need: Should Stakeholders Align on a Definition?
IP4: Value Added Medicines: Time to Adjust the Health Technology Assessment Decision Frameworks?
W3: Making Patient Reported Outcomes Measurement Meaningful: Best Practices for Presenting Patient Reported Outcomes Data to Patients, Clinicians, and Decision Makers
W4: Bridging the Gap: Best Practices in Navigating Diverging Perceptions of Regulators and Payers on Non-Traditional Clinical Trial Endpoints
P3: Studies on Health Technology Assessment Agencies
P4: Research on Methods

15:15-15:45  BREAK & EXHIBITS

15:45-19:30  POSTERS - SESSION II

15:45-16:45  BREAKOUT SESSION
IP5: Title TBD
IP6: Are Existing Health Technology Assessment Requirements Inadequate for Establishing Value for Potentially Transformative Gene Therapies?
W5: Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions?
W6: Generating Real-World Evidence for Real-World Decisions: Application of Advanced Methods
P5: Medication Adherence Studies
P6: Mental Health Studies

17:00-18:00  BREAKOUT SESSION
IP7: ‘Mind the Gap!’: How Should We Manage the Difference Between Regulatory and Reimbursement Evidence Requirements for Medical Devices?
IP8: Forecasting Pharmaceutical Expenditure in Europe: Is It Sustainable?
W7: Value of Information (VOI) Analysis for Research Decisions: Emerging Good Practice Recommendations from the ISPOR VOI Task Force
W8: Modeling Separate Lines of Treatment Versus Treatment Sequences in Cancer
P7: Conceptual Papers
P8: Cardiovascular Studies

* Program subject to change
18:00-19:30  EXHIBITORS' OPEN HOUSE RECEPTION & POSTERS - SESSION II

18:15-19:15  BREAKOUT SESSION
F2: Update of the Oncology Health Economic Modeling Working Group of the ISPOR Oncology Special Interest Group
F3: Rare Disease Research, Health Technology Assessment, and Evidence for Reimbursement
F4: Could Multi-Stakeholder Partnership Improve Patient Access to Better Healthcare in Latin America?
F5: Late Stage Oncology MCDA Criteria Implementation Results in European Countries
F6: The Establishment of Negotiation Committee, Therapeutic Guidelines, and Health Technology Assessment Efforts in Central and Eastern European Countries

18:30-19:30  POSTER AUTHOR DISCUSSION HOUR - SESSION II

TUESDAY, 7 NOVEMBER

7:30-8:30  EDUCATIONAL SYMPOSIUM
Changing the Health Technology Assessment Paradigm: Beyond Clinical and Economic Evaluation for Innovative Drugs (Sponsored by Takeda Pharmaceuticals International GmbH)

8:30-19:15  EXHIBIT HOURS

8:45-13:30  POSTERS - SESSION III

8:45-9:45  BREAKOUT SESSION
IP9: Should Rare Oncology Treatments Be Considered True Orphans?
IP10: Does Valuation of Innovation in Appraisal of New Technologies Provide Appropriate Incentives for Manufacturers and Access for Patients?
W10: EQ-5D: Is NICE Ready for the Next Level?
P9: Medical Device and Diagnostics Studies
P10: Methods in Patient Preference Studies

9:45-10:15  BREAK, EXHIBITS & POSTERS - SESSION III

10:15-12:00  WELCOME & SECOND PLENARY SESSION
Appraising the Appraisers: What Is the Future of Health Technology Assessment in Europe?

12:00-14:00  LUNCH, EXHIBITS & POSTERS - SESSION III

12:30-13:30  EDUCATIONAL SYMPOSIUM
Practical Implications of Value-Based Pricing and Emerging Value Frameworks in Health Technology Assessment (Sponsored by Xcenda)

13:00-15:00  POSTER AUTHOR DISCUSSION HOUR - SESSION III

15:00-15:30  BREAK & EXHIBITS

15:30-19:15  POSTERS - SESSION IV

15:30-16:30  BREAKOUT SESSION
IP13: TBD
W14: Getting to the Heart of the Matter: Real-World Evidence as an Indispensable Source for the Ongoing Assessment of Cardiovascular Treatments
W15: Time for a Change? Alternative Approaches to Modelling in Cancer Value Assessments
W16: Understanding the Value and Feasibility of Engaging Patients in the Design of Clinical Trials and Clinical Outcome Assessment Measurement Strategies: Insights From Experiences in Oncology and Gout
P13: Methodological Studies in Cancer
P14: Systemic Disorders/Conditions Studies

16:45-17:45  BREAKOUT SESSION
IP15: A Modest Proposal: Can We Ease the Burden of Myriad Measures With a Minimum Data Set That Actually Matters to Patients?
IP16: Managed Entry Schemes for Medical Devices: Great Opportunity or Major Challenge?
W17: Why is Your Outcome Different from Mine? Discussing the Potential Impact of Design Choices in the Development of Discrete Event Simulation Models
W18: Understanding the Value and Feasibility of Engaging Patients in the Design of Clinical Trials and Clinical Outcome Assessment Measurement Strategies: Insights From Experiences in Oncology and Gout
P15: Health Technology Assessment Studies
P16: Infectious Disease Studies

17:45-19:15  EXHIBITORS’ WINE & CHEESE RECEPTION & POSTERS - SESSION IV

18:00-19:00  BREAKOUT SESSION
F7: Health State Utility Identification and Use in Cost-Effectiveness Decision Modelling – An ISPOR Task Force
F8: Innovation and Market Access in Asia-Pacific: What Evidence and Processes Are Appropriate for Reimbursement? China, Japan, South Korea, Taiwan, and Australia Compared
F9: Rare Diseases MCDA Criteria Implementation Results in European Countries
F10: The Burden of COPD in Central and Eastern Europe
F11: The New Paradigm of Cancer Treatments: A Challenge for the Health Systems?

* Program subject to change
Join us for an evening of Ceilidh dancing and a variety of dining options at Merchant Square, located in the heart of the Merchant City, Glasgow's cultural, fashion, and food quarter.

**EDUCATIONAL SYMPOSIUM**

**Universal Value: The Way Forward?** *(Sponsored by Covance)*

**EXHIBIT HOURS**

**POSTERS - SESSION V**

**BREAKOUT SESSION**

IP17: Deriving Utility Measures from Disease-Specific Quality of Life Instruments: Does Mapping to Generic Utility Instruments Adequately Capture the Patient Perspective in Economic Evaluation?

IP18: How Will Health Care Systems Handle Future Oncology Combination Product Launches?

IP19: Can the Patient Voice Be Better Incorporated into the NICE Process?

W17: Comparing, Contrasting, and Validating Health Economic Decision Models: Experiences From the Latest Mt. Hood Challenge in Diabetes and Lessons for Other Disease Areas

W18: From One to Many: When Groups – Not Czars – Make Decisions

**BREAK, EXHIBITS & POSTERS - SESSION V**

**BREAKOUT SESSION**

IP20: Should ICER Be Nice (Or Not)? How ICER's New Cost-Effectiveness Framework Compares with NICE's Guidelines

IP21: Adaptive Pathways for Transformative Medicinal Products: A New Paradigm With the Enhanced Application of Real-World Evidence?

IP22: mHealth Among Clinicians and Patients in Cancer Care: How to Address the Digital Divide?

IP23: Improving Performance of Algorithms to Power Unmet Need Ready?

W21: Comparing Treatments by Combining Data From Various Randomized and Observational Studies: Introduction to Concept, Methods, and Application

W22: Negotiating Price and Data in an Era of Conditional Approval: “Stick” or “Twist”? 

**BREAK**

**BREAKOUT SESSION**

IP24: How Do You Incorporate the Patient Perspective into Health Technology Assessments? Defining Best Practices for Rigorous Scientific Evidence and Impactful Submissions and Reviews

IP25: Innovative Clinical Trial Designs: Welcomed by Regulators But What about the Payers?

W23: Population-Adjusted Treatment Comparisons in Health Economics and Outcomes Research and Effectiveness in Health Economics and Outcomes Research

W24: Disconnected or Limited Evidence in Network Meta-Analysis: What Can Be Done?

**EDUCATIONAL SYMPOSIUM**

**(Sponsored by Astra Zeneca)**

**CONGRESS REGISTRATION FEES**

<table>
<thead>
<tr>
<th>Category</th>
<th>Through 19 September 2017</th>
<th>After 19 September 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>Member €900 (US$990)  Non-Member €1060 (US$1155)</td>
<td>Member €1,000 (US$1090)  Non-Member €1,160 (US$1265)</td>
</tr>
<tr>
<td>Clinical Practitioners (Clinical Practice, Hospital)</td>
<td>Member €700 (US$765)  Non-Member €860 (US$940)</td>
<td>Member €800 (US$870)  Non-Member €960 (US$1045)</td>
</tr>
<tr>
<td>Full-Time Government and Academia</td>
<td>Member €600 (US$655)  Non-Member €760 (US$830)</td>
<td>Member €700 (US$765)  Non-Member €860 (US$940)</td>
</tr>
<tr>
<td>Patient Representative</td>
<td>Member €250 (US$275)  Non-Member €415 (US$450)</td>
<td>Member €300 (US$330)  Non-Member €465 (US$505)</td>
</tr>
<tr>
<td>Full-Time Students (must provide current enrollment docs)</td>
<td>Member €200 (US$220)  Non-Member €260 (US$280)</td>
<td>Member €250 (US$275)  Non-Member €310 (US$335)</td>
</tr>
<tr>
<td>One Day Registration (per day)</td>
<td>Member €425 (US$465)  Non-Member €590 (US$640)</td>
<td>Member €425 (US$465)  Non-Member €590 (US$640)</td>
</tr>
</tbody>
</table>

**CONGRESS ENHANCEMENT FEES**

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Course Continuing Education Accreditation (CPE &amp; CME)</td>
<td>€115 (US$125)</td>
</tr>
<tr>
<td>ISPOR Social Event: Merchant Square (includes food, drinks, and Scottish dancing)</td>
<td>€90 (US$98)</td>
</tr>
</tbody>
</table>

**Hotel/Venue Information**: The ISPOR 20th Annual European Congress will be held at the Scottish Event Campus (SEC) located just outside Glasgow city center in the west-end. The campus is easily accessible by numerous transport options. The Glasgow Convention Bureau is the official accommodation provider for the conference and has negotiated specially discounted rates with a wide range of hotels in different categories. Accommodation will be sold on a first come, first served basis and the published rates will be available until 15 September 2017. Visit the ISPOR Glasgow website to secure your discounted rate! (http://www.ispor.org/Event/HotelVenueInformation/2017Glasgow).
A simple, yet powerful, tool to get the most out of your ISPOR congress experience.

• Search for sessions, courses, and posters by topic, keyword, or speaker
• Create a personalized meeting schedule
• Connect with other attendees via the meeting messaging platform (while keeping your email address private)
• Customize your “electronic business card”
• Find attendees, exhibitors, and sponsors to meet with and expand your network
• Tour virtual booths

DOWNLOAD INFORMATION

Congress registrants will have access to congress content and functionality within the app approximately one month prior to the European Congress. Download the mobile app on your smartphone or tablet.

SEARCH: ISPOR

© 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)